The clinical efficacy of eribulin to soft tissue sarcoma patients: differences in histological subtypes

Abstract

Abstract Background In Japan, eribulin can be indicated to all histology of STS and available as 2nd or later line chemotherapy; however, the clinical evidence of eribulin to STS based on the international randomized clinical trial is limited to L-sarcoma (leiomyosarcoma and liposaroma) as 3rd or later line chemotherapy yet. Methods We retrospectively reviewed STS patients treated with eribulin between March 2016 and December 2018 in our institute. Prognoses of all patients, differences of prognoses by histology (comparison of L-sarcoma and other histology) and differences of prognoses by treatment line (comparison of 2nd line and later line) in L-sarcoma were evaluated. Results Total of 41 patients were enrolled in the analysis; 26 of them were L-sarcoma and 15 were other histology. In 26 L-sarcoma patients, 12 patients was leiomyosarcoma and the other 14 was liposarcoma. Among L-sarcoma patients, the media PFS was longer in liposarcoma (8.42 months, 95% CI: 5.67-11.17) than leiomyosarcoma (2.3 months, 95% CI: 1.35-3.32) significantly (p = 0.021), but there were not differences in the median OS between liposarcoma (24.4 months, 95% CI: 6.14-42.59) and leiomyosarcoma (21.90 months, 95% CI: 0.76-43.03) significantly (p = 0.568). Conclusion Eribulin showed longer prognoses in L-sarcoma, especially in liposarcoma in terms of the PFS.